[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Odyssey Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100581470",false,"NCT06850727","Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis","A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a confirmed diagnosis of ulcerative colitis (UC)\n* Has moderate to severely active UC as defined by the 3-component Modified Mayo clinic score\n* Has an inadequate response, loss of response, or intolerance\u002Fmedical contraindication to at least one of the following therapies: oral aminosalicylates, corticosteroids, immunosuppressants, anti-tumor necrosis factor biologic, anti-interleukin 12\u002F23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has diagnosis of Crohn's disease or indeterminate colitis\n* Has had extensive colonic resection\n* Has colostomy or ileostomy\n* Has uncontrolled primary sclerosing cholangitis","ALL","18 Years","75 Years",{"count":19,"type":20},57,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.",[26,27],"Ulcerative Colitis (UC)","UC - Ulcerative Colitis",[29,30],"Ulcertative colitis","Inflammatory Bowel Diseases","RECRUITING","2026-02-09",{"date":34,"type":35},"2026-02-11","ACTUAL",{"date":37,"type":35},"2025-06-02",{"date":39,"type":20},"2026-11",{"name":41,"class":42},"Odyssey Therapeutics","INDUSTRY",32,""]